Ningbo Menovo Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Ningbo Menovo Pharmaceutical's earnings have been declining at an average annual rate of -13%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.8% per year. Ningbo Menovo Pharmaceutical's return on equity is 1.1%, and it has net margins of 1.6%.
Key information
-13.0%
Earnings growth rate
-14.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 0.8% |
| Return on equity | 1.1% |
| Net Margin | 1.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Ningbo Menovo Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,237 | 20 | 214 | 95 |
| 30 Jun 24 | 1,242 | 0 | 222 | 102 |
| 31 Mar 24 | 1,233 | -18 | 223 | 100 |
| 31 Dec 23 | 1,216 | 12 | 220 | 95 |
| 30 Sep 23 | 1,155 | 179 | 242 | 91 |
| 30 Jun 23 | 1,142 | 185 | 239 | 90 |
| 31 Mar 23 | 1,203 | 267 | 237 | 101 |
| 31 Dec 22 | 1,457 | 339 | 248 | 98 |
| 30 Sep 22 | 1,570 | 221 | 235 | 109 |
| 30 Jun 22 | 1,464 | 211 | 217 | 106 |
| 31 Mar 22 | 1,420 | 207 | 209 | 84 |
| 31 Dec 21 | 1,258 | 143 | 196 | 88 |
| 30 Sep 21 | 1,163 | 150 | 170 | 88 |
| 30 Jun 21 | 1,234 | 166 | 170 | 78 |
| 31 Mar 21 | 1,246 | 163 | 178 | 79 |
| 31 Dec 20 | 1,193 | 156 | 169 | 74 |
| 30 Sep 20 | 1,278 | 164 | 210 | 56 |
| 30 Jun 20 | 1,270 | 171 | 209 | 55 |
| 31 Mar 20 | 1,211 | 152 | 191 | 52 |
| 31 Dec 19 | 1,180 | 151 | 186 | 53 |
| 30 Sep 19 | 1,142 | 160 | 157 | 50 |
| 30 Jun 19 | 1,062 | 138 | 146 | 45 |
| 31 Mar 19 | 949 | 131 | 144 | 40 |
| 31 Dec 18 | 849 | 96 | 131 | 39 |
| 30 Sep 18 | 735 | 73 | 110 | 33 |
| 30 Jun 18 | 650 | 57 | 88 | 46 |
| 31 Mar 18 | 615 | 39 | 87 | 40 |
| 31 Dec 17 | 605 | 45 | 97 | 32 |
| 30 Sep 17 | 560 | 53 | 95 | 20 |
| 30 Jun 17 | 584 | 71 | 111 | 0 |
| 31 Mar 17 | 595 | 80 | 107 | 0 |
| 31 Dec 16 | 578 | 79 | 106 | 0 |
| 31 Dec 15 | 597 | 77 | 106 | 0 |
| 31 Dec 14 | 636 | 73 | 102 | 0 |
| 31 Dec 13 | 502 | 69 | 79 | 0 |
Quality Earnings: 603538 has a large one-off gain of CN¥25.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 603538's current net profit margins (1.6%) are lower than last year (15.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603538's earnings have declined by 13% per year over the past 5 years.
Accelerating Growth: 603538's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603538 had negative earnings growth (-88.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 603538's Return on Equity (1.1%) is considered low.